Chen et al. administered 8 stage III/IV GIST patients with PegIFNα2b, and found that 4-week combination therapy induced a large amount of IFNγ and increased the infiltration of IFNγ producing CD4+ T, CD8+ T and NK cells [193, 225, 226]. The gene discussed is CD8A; the disease is gastrointestinal stromal tumor.